📍 Barcelona, April 2025
The New Pharma Reality: Execution > Innovation
At Reuters Pharma 2025, over a thousand life sciences leaders gathered in Barcelona—not to celebrate clinical wins, but to confront a harsh truth: scientific innovation alone no longer guarantees success. Despite historic R&D output, pharma launches continue to stall, margins erode, and engagement costs rise.
The conference made one thing clear: the path forward is about speed, integration, and measurable value, not just molecules.
3 Strategic Fault Lines Exposed
1. Organisational Design
Companies with fully integrated launch squads—medical, digital, market access, and analytics under one roof—are outpacing their peers. The key lever? Governance, not headcount.
2. Data Infrastructure
AI and omnichannel tools demand a cloud-native, compliant data fabric. Without it, pilots die and messaging regresses. Treat your data like capital equipment—or risk irrelevance.
3. Early Partnerships
Engaging payers and patient groups from Phase IIb (not post-launch) shortens access timelines and protects pricing power. Value co-creation is no longer optional.
Where AI Meets Workflow
Artificial Intelligence is no longer sitting in the innovation lab. At Reuters Pharma 2025, a key takeaway was that AI is being operationalized inside the commercial workflow, not just layered onto it. The technology has matured beyond marketing hype and delivers tangible results across the pharmaceutical value chain.
AI in Action: From Repetition to Optimization
Pharma leaders from Sanofi, Astellas, and others showcased real-world applications where AI is streamlining the day-to-day grind:
- Sales Enablement: AI-powered field orchestration engines are drafting call notes based on live customer interactions, allowing reps to spend more time engaging and less time documenting.
- Clinical Trials: Trial-site platforms use AI to instantly generate and manage investigator contracts, reducing what used to take weeks to minutes.
- Regulatory Affairs: AI-driven value-dossier tools generate the first drafts of submissions, freeing experts to refine rather than build from scratch.
These use cases show a shift from AI as a content generator to AI as an operational teammate—optimizing time, reducing manual error, and lowering costs across departments.
Grab your copy of the Reuters Pharma 2025 PDF for deeper insights and the full breakdown on what’s ahead in the industry.
Compliance Built-In, Not Bolted On
But none of this works without robust governance. The companies seeing the most significant ROI aren’t just using AI—they’re embedding real-time compliance guardrails into the workflow. This ensures that while speed increases, regulatory risk does not.
In fact, organizations that adopt this dual approach—automation plus compliance—are achieving double-digit reductions in cost and time-to-market. The message? AI doesn’t just help you work faster; it enables you to work smarter and safer.
A Strategic Asset, Not a Side Project
Forward-thinking companies are now treating AI algorithms as living assets. That means giving them a budget, product owner, and roadmap like any other strategic initiative. Some have even started embedding AI product owners directly within therapy-area teams, rather than burying them inside IT.
The bottom line: AI is no longer an experimental tool. It’s becoming integral to how pharma builds, sells, and scales therapies in a post-pandemic, data-regulated world.
Digital Health: From App to Ecosystem
In a standout session led by Roberta Pandolfi (Boehringer Ingelheim), panelists admitted the painful truth: no one in the room runs a digital health app with 10M users. Aspirations are high, but scalability remains elusive.
The winning mindset? Stop chasing point solutions. Start building ecosystems that compound in value.
The Road Ahead: What Pharma Leaders Must Do Now
The post-conference roadmap is blunt but straightforward:
- Unify ownership: Appoint a franchise lead with absolute budget authority.
- Capitalise data: Move from OPEX to CAPEX for your data infrastructure.
- Embed AI stewards: Don’t silo AI in IT—put owners inside therapy teams.
- Co-create value early: Involve payers and patients before the launch phase.
- Pay for outcomes: Tie compensation to measurable, patient-centric KPIs.
Countdown to Paris: April 29 at Customer Times
Join us next at Customer Times in Paris for Innovation Day CH | Paris 2025. We’ll explore how commercial operations must evolve and how your organisation can lead the charge.
Whether you’re a pharma exec, a digital health innovator, or a transformation leader, this next event is where strategy meets action.
About Kainjoo & Allegory Capital
Kainjoo.life: Your brand-tech partner in building future-proof pharma organizations.
Allegory Capital: The VC-as-a-service unlocking digital health ventures.
Let’s stop polishing pilots. Let’s build the future—together.
✍️ By Haider Alleg, Founder at Kainjoo & GP at Allegory Capital
